Childhood liver cancer survival rates plateau at 80%, leaving one in five patients facing treatment failure with few options. The barrier lies in cisplatin resistance, where tumors evolve sophisticated DNA repair mechanisms that neutralize the standard chemotherapy regimen that has defined pediatric hepatoblastoma care for decades.
Investigators identified ATR (Ataxia Telangiectasia and Rad3-related protein) as a critical vulnerability in resistant hepatoblastoma cells. Using elimusertib, a potent ATR inhibitor, researchers demonstrated powerful synergy when combined with cisplatin across fourteen hepatoblastoma cell lines and patient-derived tumor cultures. The combination triggered enhanced DNA damage accumulation and p53-mediated cell death, effectively dismantling the repair pathways that enable resistance. In animal models, the dual therapy significantly suppressed tumor growth while maintaining manageable toxicity profiles.
This represents a precision approach targeting DNA damage response machinery rather than attempting to overwhelm resistance with higher cisplatin doses. ATR functions as a cellular checkpoint guardian, detecting DNA replication stress and coordinating repair responses. By blocking this pathway, elimusertib forces cancer cells into a vulnerable state where cisplatin damage becomes lethal. The strategy mirrors successful applications in adult cancers but represents novel territory for pediatric liver tumors. While promising, the findings require clinical validation to establish dosing, safety margins, and efficacy in children. If successful, this combination could transform outcomes for the 20% of hepatoblastoma patients who currently exhaust standard therapeutic options.